PE20230850A1 - Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion - Google Patents

Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion

Info

Publication number
PE20230850A1
PE20230850A1 PE2023001480A PE2023001480A PE20230850A1 PE 20230850 A1 PE20230850 A1 PE 20230850A1 PE 2023001480 A PE2023001480 A PE 2023001480A PE 2023001480 A PE2023001480 A PE 2023001480A PE 20230850 A1 PE20230850 A1 PE 20230850A1
Authority
PE
Peru
Prior art keywords
indol
pyrazole
cyano
isopropyl
carboxylic acid
Prior art date
Application number
PE2023001480A
Other languages
English (en)
Inventor
Seok Cheol Yoo
Joomyung Jang
Ree Sun Kim
Jin A Seo
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of PE20230850A1 publication Critical patent/PE20230850A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion esta referida a una formulacion oral caracterizada porque comprende un ingrediente farmaceutico activo (API) seleccionado de acido 1-(3-ciano-1-isopropil-indol-5- il)pirazol-4-carboxilico o una sal farmaceuticamente aceptable de este; y un fluidificante, en donde el fluidificante se selecciona del grupo que consiste en dioxido de silicio coloidal, dioxido de silicio hidratado y combinaciones de estos. Esta formulacion se emplea para inhibir la xantina oxidasa que puede prevenir la deposicion de acido urico en el cuerpo, y, por lo tanto, es util para tratar enfermedades relacionadas con la xantina oxidasa tales como hiperuricemia, gota, insuficiencia cardiaca, enfermedades cardiovasculares, tension arterial alta, diabetes, enfermedades renales, enfermedades de las articulaciones y enfermedad inflamatoria intestinal.
PE2023001480A 2020-12-01 2021-11-30 Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion PE20230850A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200165790 2020-12-01
PCT/KR2021/017843 WO2022119270A1 (ko) 2020-12-01 2021-11-30 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 경구용 제제, 및 그의 제조방법

Publications (1)

Publication Number Publication Date
PE20230850A1 true PE20230850A1 (es) 2023-05-23

Family

ID=81854229

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001480A PE20230850A1 (es) 2020-12-01 2021-11-30 Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion

Country Status (15)

Country Link
US (1) US20240173259A1 (es)
EP (1) EP4257124A4 (es)
JP (1) JP2023551524A (es)
KR (1) KR20220077092A (es)
CN (1) CN116528853A (es)
AR (1) AR124180A1 (es)
AU (1) AU2021392532A1 (es)
BR (1) BR112023009427A2 (es)
CA (1) CA3195598A1 (es)
CL (1) CL2023001061A1 (es)
CO (1) CO2023005206A2 (es)
MX (1) MX2023005461A (es)
PE (1) PE20230850A1 (es)
TW (1) TW202231270A (es)
WO (1) WO2022119270A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
BRPI0810524B8 (pt) * 2007-04-11 2021-05-25 Kissei Pharmaceutical derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
CN116456979A (zh) * 2020-11-04 2023-07-18 株式会社Lg化学 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸结晶粒子的制备方法以及包含其的药物组合物

Also Published As

Publication number Publication date
TW202231270A (zh) 2022-08-16
EP4257124A1 (en) 2023-10-11
US20240173259A1 (en) 2024-05-30
EP4257124A4 (en) 2024-05-29
AU2021392532A1 (en) 2023-06-29
CA3195598A1 (en) 2022-06-09
MX2023005461A (es) 2023-05-22
BR112023009427A2 (pt) 2024-02-06
AR124180A1 (es) 2023-02-22
JP2023551524A (ja) 2023-12-08
CL2023001061A1 (es) 2023-12-11
CO2023005206A2 (es) 2023-04-27
WO2022119270A1 (ko) 2022-06-09
CN116528853A (zh) 2023-08-01
KR20220077092A (ko) 2022-06-08

Similar Documents

Publication Publication Date Title
JP2013543492A5 (es)
AR079930A2 (es) Formulaciones de inhibidores de dipeptidil peptidasa iv (dpp iv)
NO312578B1 (no) Farmasöytisk kombinasjonspreparat
TW200817000A (en) New paediatric indications for direct thrombin inhibitors
JP2023501221A (ja) バダデュスタットを使用する治療方法
PE20230850A1 (es) Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
JP2020514411A (ja) チオールイソメラーゼ阻害剤およびその使用
AU2018263059A1 (en) Compositions and treatment procedures for the treatment of pathogenic infections
IL312296A (en) 3-PHENYL-1-BENZOTHIOPEN-2-CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF BRANCHED ALPHA KETO ACID DEHYDROGENSIS KINASE FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART
AR111313A1 (es) Composición osmóticamente activa para diálisis
JP2008019221A (ja) 動脈瘤の予防及び／又は治療薬
RU2011134414A (ru) Комбинация фульвовой кислоты для лечения различных состояний и болезней
EP2586442A1 (en) Sustained-release therapeutic agent for hypertension and renal dysfunction
PE20240222A1 (es) Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico y un proceso para su preparacion
JP2010529113A (ja) ピラゾロピリミジノン誘導体化合物を含む慢性心不全治療用医薬組成物
PE20240764A1 (es) Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico
MX2023014359A (es) Una composicion farmaceutica que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxilico.
BR112015024462A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor da xantina oxidase, e, agente terapêutico ou profilático para uma doença
US20240041857A1 (en) Pharmaceutical composition for treatment of aortic aneurysm
EP3842056B1 (en) Use of ghrp-6 as late cardioprotective and cardiac restoration medicament
EP4302787A1 (en) Hydroxyethycellulose gel compositions comprising bacteriophages
Lehmann F et al. Compromiso cardiovascular en pacientes pediátricos en diálisis peritoneal crónica
US20230072496A1 (en) Polypeptide compositions and uses thereof
STOICHESCU et al. Particularities of multivessel disease in a diabetic patient
TH104398B (th) การใช้ยูเรตออกซิเดสเพื่อการรักษาหรือการป้องกันความผิดปกติหรือผลกระทบทางอ้อมที่ตามมาของหัวใจที่เกิดจากภาวะพร่องเลือดหรือผ่านเลือด